Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.7399
-0.0251 (-3.28%)
At close: Jun 9, 2026, 4:00 PM EDT
0.7301
-0.0098 (-1.32%)
Pre-market: Jun 10, 2026, 7:23 AM EDT
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
2.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 29.57M |
| Ensysce Biosciences | 4.71M |
| VivoSim Labs | 142.00K |
| Biodexa Pharmaceuticals | 104.90K |
| Azitra | 7.50K |
VBIO News
- 12 days ago - Valion Bio Transcript: AGM 2026 - Transcripts
- 21 days ago - VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME - PRNewsWire
- 26 days ago - Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform - TheFly
- 26 days ago - Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year - TheFly
- 26 days ago - Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - PRNewsWire
- 26 days ago - Valion Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 26 days ago - Valion Bio Earnings release: Q1 2026 - Filings
- 26 days ago - Valion Bio Quarterly report: Q1 2026 - Filings